BioMarin Appoints Industry Veterans from Amgen and Roche in Executive Revamp

BioMarin has appointed Greg Friberg, formerly of Amgen, as EVP, Chief Research & Development Officer, and James Sabry, formerly of Roche, as Chief Business Officer.
These appointments are part of an executive restructuring aimed at implementing a more focused strategy for BioMarin's Roctavian hemophilia A gene therapy.
The company is narrowing its sales effort for Roctavian to focus on the U.S., German, and Italian markets to lower yearly direct expenditure to around $60 million starting in 2025.
Hank Fuchs, who previously held the position of Chief Research & Development Officer, will retire after 15 years at BioMarin but will stay as an advisor through March 3, 2025.
BioMarin aims to apply its science-driven, patient-forward approach to larger genetic disorders and genetic subsets of more common conditions.